STUDY OF ORAL RS 25560197 IN PATIENTS WITH CONGESTIVE HEART FAILURE

充血性心力衰竭患者口服 RS 25560197 的研究

• 批准号: 6276088
• 负责人: EDWARD M GILBERT
• 金额: $ 2.66万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276088
• 关键词: clinical research; congestive heart failure; drug adverse effect; drug screening /evaluation; heart disorder chemotherapy; human subject; human therapy evaluation; norepinephrine; oral administration; serotonin inhibitor

The objective of this study will be to evaluate the safety and tolerability of single and multiple (10 day) dose oral administration of RS-25560 in patients with CHF (NYHA class II or III) and elevated plasma norepinephrine levels.

这项研究的目的是评估安全性和 单次和多个（10天）口服的耐受性 CHF患者（NYHA II或III）患者的RS-25560 血浆去甲肾上腺素水平。